| P2093 | author name string | Yang Song | |
| | Chong He | |
| | Jun-Shan Wang | |
| | Zhan-Ju Liu | |
| | Yan-Hong Shi | |
| | Yu-Jie Zhao | |
| | Chang-Qin Liu | |
| | Rui-Jin Wu | |
| | Xiao-Yue Feng | |
| | Yan-Min Guo | |
| P2860 | cites work | Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study | Q24816844 |
| | Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease | Q26822029 |
| | Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus | Q26852581 |
| | Hypersensitivity vasculitis and Henoch-Schönlein purpura: a comparison between the 2 disorders. | Q34447687 |
| | Vasculitis associated with tumor necrosis factor-α inhibitors | Q36513081 |
| | Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review | Q37560336 |
| | Autoimmune diseases induced by biological agents: a double-edged sword? | Q37620986 |
| | Henoch-Schonlein purpura nephritis: pathophysiology, treatment, and future strategy | Q37851769 |
| | Anti-TNF therapy: safety aspects of taking the risk | Q37875392 |
| | Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. | Q38085904 |
| | Henoch-Schönlein purpura complicating adalimumab therapy for Crohn's disease | Q42730509 |
| | Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission | Q43856550 |
| | Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis | Q44104683 |
| | Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study | Q44673417 |
| | Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab | Q44742543 |
| | Gastrointestinal involvement in Henoch-Schönlein purpura | Q44789500 |
| | Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). | Q44791207 |
| | Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. | Q45093383 |
| | Herpes zoster infection followed by Henoch-Schönlein purpura in a girl receiving infliximab for ulcerative colitis. | Q51781780 |
| | Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. | Q52859775 |
| | B cell activation in rheumatoid arthritis patients under infliximab treatment | Q75323122 |
| | Henoch-Schönlein purpura after etanercept therapy for psoriasis | Q79195457 |
| | Henoch Schönlein purpura following etanercept treatment of rheumatoid arthritis | Q79960453 |
| | Tumor necrosis factor-alpha blockade and the risk of vasculitis | Q80829140 |
| | Reversible Henoch-Schönlein purpura complicating adalimumab therapy | Q83737689 |
| | Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies | Q83836843 |
| | Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy | Q87181170 |
| | Skin reactions during anti-TNFα therapy for pediatric inflammatory bowel disease: a 2-year prospective study | Q88057694 |
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 6082-6087 | |
| P577 | publication date | 2015-05-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Severe Henoch-Schönlein purpura with infliximab for ulcerative colitis | |
| P478 | volume | 21 | |